What Health Catalyst (HCAT) Said on Its Q3 Earnings Call
Health Catalyst (HCAT) reported Q3 revenue of $56.3M ($40.7M tech, $15.6M services), with adjusted gross margin falling to 44.3% from 52.6% YoY. Adjusted net loss was $0.03 per share. The company expects a Q4 adjusted EBITDA loss of $1.8M-$1.3M, citing Vitalware's removal and higher medical claims. HCAT ended Q3 with $79M in cash and no debt.
How this was made

The 30-second read
Why it matters
The earnings miss and guidance suggest near‑term downside risk, but cash reserves provide a cushion.
Market read
Earnings release is the primary catalyst for HCAT's near‑term price action.
What to watch
Potential cost savings from Project Nexus and the removal of Vitalware may improve future profitability.
Background
Health Catalyst reported Q3 technology and services revenue, margin compression, and a loss outlook for Q4.
Ticker impact
Q3 earnings disclosed lower margins and a Q4 adjusted EBITDA loss guidance of $1.8M‑$1.3M.
downside pressure as investors price in margin compression and loss guidance
The article provides the first report of Q3 results with declining margins and a loss outlook, which typically moves the stock lower.
Market effects
Highlights pressure on healthcare‑tech firms with high services cost structures.
US healthcare‑tech segment may see modest pullback.
Limited to investors tracking US health‑data analytics stocks.
Counterpoint
If the cash position remains strong and the loss is one‑time, the stock could be undervalued.
Key entities
- companyHealth Catalyst, Inc.
Healthcare technology firm providing data and analytics solutions.



